<DOC>
	<DOC>NCT02613507</DOC>
	<brief_summary>The purpose of this study is to determine whether Nivolumab improves life expectancy compared to Docetaxel in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who have failed prior platinum-based doublet chemotherapy.</brief_summary>
	<brief_title>Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Disease progression experienced during or after one prior platinum containing doublet chemotherapy Stage IIIb/IV or recurrent disease Male and Female ≥ 18 years of age Measurable disease per RECIST 1.1 Performance Status ≤ 1 History of Carcinomatous meningitis Active Central nervous system (CNS) metastases History of auto immune diseases Prior treatment with Docetaxel Prior treatment with ipilimumab or any drug targeting TCell costimulation or checkpoint pathways</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>